Clinical Trial

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-09-20; most recent amendment 2026-01-29.
Status change: Recruiting → Active, Not Recruiting 2026-01-29
Trial Details
NCT Number NCT06610526
Lead Sponsor AstraZeneca
Conditions Chronic Kidney Disease
Enrollment 731 participants
Start Date 2024-08-23
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-30